EUCTR2014-003120-48-FR进行中（未招募）1 期
Etude des modulations du système immunitaire des patients atteints de mélanome et traités par anticorps monoclonaux anti-PD1.Etude concernant les patients atteints de mélanome métastatique
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age = 18 ans
- •- Patients porteurs d’un mélanome cutané en rechute métastatique
- •- Chez lesquels un traitement par anticorps anti-PD1 est indiqué
- •- Affiliation à un régime de sécurité sociale
- •- Consentement éclairé signé
- •- Patient acceptant la conservation de ses échantillons biologiques
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Tumeurs hématologiques en cours de traitement
- •- Patient nécessitant un traitement au long cours par corticostéroïdes systémiques ou par tout autre agent immunosuppresseur
- •- Antécédents de maladies auto-immunes
- •- Mélanome oculaire
研究者
相似试验
进行中（未招募）
不适用
Regulatory role of the immune system of Prevenar 13 vaccine in children with asthma and diabetes.Allergic asthma and type 1 diabetes mellitus in pediatric subjects.EUCTR2014-004799-50-ESFederico Martinon Torres
尚未招募
不适用
Characterization of aberrant immune response in post-COVID using innovative signal transduction pathway technology (LC-STP)Long-COVIDPost-COVID1002766510047438NL-OMON56864Academisch Medisch Centrum50
尚未招募
2 期
Examinations for immune-biological mechanism of anti-atherosclerotic effects of omega 3 lipid formula, Lotriga, focusing on commensal microbe and serum auto-antibodies.The subjects with hyper-triglyceridemia and atherosclerosis.JPRN-UMIN000032320Yokohama City University Graduate School of Medicine, Department of Medical Science and Cardio-Renal Medicine36
尚未招募
不适用
Dynamic changes of immune-related molecules of peripheral blood in patients treated immunotherapy with advanced non-small cell lung cancerPatients diagnosed with advanced non-small cell lung cancer (NSCLC: Non-Small-Cell-Lung-Cancer) scheduled to receive immunotherapy and combined immunotherapyJPRN-UMIN000042885Tohoku Medical and Pharmaceutical University,Tohoku Medical and Pharmaceutical University Hospital50
进行中（未招募）
不适用
Investigation of immune mechanisms relating to lapatinib associated hepatotoxicity (liver toxicity)The subjects participated in the EGF105485 study, a randomized, placebo-controlled study of lapatinib in HER2-positive early-stage breast cancer. During participation in this study, subjects had blood test results that may be suggestive of liver damage.EUCTR2013-000572-15-ESGlaxoSmithKline, S.A.75